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Acute coronary syndromesFractional ﬂow reserve (FFR) assessment provides anatomical and physiological information that is often used to
tailor treatment strategies in coronary artery disease.Whilst robust data validates FFR use in stable ischaemic heart
disease, its use in acute coronary syndromes (ACS) is less well investigated. We critically review the current data
surrounding FFR use across the spectrum of ACS including culprit and non-culprit artery analysis. With adenosine
being conventionally used to induce maximal hyperaemia during FFR assessment, co-existent clinical conditions
may preclude its use during acute myocardial infarction. Therefore, we include a current review of instantaneous
wave free ratio as a novel vasodilator independentmethod of assessing lesion severity as an alternative strategy to
guide revascularisation in ACS.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Fractional ﬂow reserve assessment in acute coronary syndromes
Acute coronary syndromes (ACS) are the only clinical condition in
which there is a proven mortality beneﬁt with percutaneous coronary
intervention (PCI) [1]. In the case of ST-elevation and acute coronary oc-
clusion, the culprit vessel is usually identiﬁable. However, bystander
coronary artery disease or multi-vessel disease occurs in approximately
one half of ACS presentations, where diagnosing the culprit lesion can
be less straight-forward with an associated poorer prognosis [2–4].
Whilst in stable coronary artery disease, physiological assessment
using techniques such as fractional ﬂow reserve (FFR) assessment is
often used to aid operators in deciding which lesion to treat [5–8], its
use in ACS is less well investigated. (See Table 1.)
Identiﬁcation of the culprit artery in ST elevation MI is usually
straight-forward by utilising information from the surface electrocar-
diogram and coronary angiography. It is recognised that FFR values in
the culprit vessel are higher during acute episodes when compared to
measurements made after the microcirculation has had some time to
recover [9,10]. It is postulated that this is due to a reduction in the
level of attainable hyperaemia in the culprit vessel due to embolisation
of thrombus andplaque, ischaemicmicrovascular dysfunction andmyo-
cardial stunning [11]. These states are perhapsmost marked in acute ST
elevation myocardial infarction. Therefore, the physiological communi-
ty remain cautious about the application of FFR in culprit artery diseaseh).
nd Ltd. This is an open access article u[12]. The use of FFR in assessing the haemodynamic signiﬁcance of non-
culprit lesions in AMI and unstable angina has only been assessed in
small studieswith differing conclusions. Some studies suggest that tran-
sitory microvascular damage in myocardial territories remote from the
culprit lesion and the dynamic nature of the injuries limit the reliability
ofmeasured indices.Whilst others suggest that FFR can be reliablymea-
sured to guide management in this population [13,14].
By demonstrating territories of inducible ischaemia in the context of
stable coronary artery disease, lesion selection for coronary intervention
can be made easier particularly in multi-vessel disease [15]. Physiologi-
cal assessment offers an invasive pressure based index of the haemody-
namic signiﬁcance of coronary stenoses and its use has been validated in
several clinical trials to guide appropriateness of PCI in stable coronary
disease [5–7].
Data suggests that complete revascularisation of patients with signiﬁ-
cantmulti-vessel diseasewithin amonth of primary PCI is associatedwith
an improved survival beneﬁt [2,3].More recent data from the randomised
PRAMI (Preventative Angioplasty in Acute Myocardial Infarction) trial
showed that immediate preventative revascularisation of non-culprit ar-
teries with an angiographically signiﬁcant stenosis at the time of primary
PCI for an ST segment elevationmyocardial infarctionmay have prognos-
tic advantages over culprit PCI alone [4,16]. It is important to note, howev-
er, that the PRAMI trial compared non-culprit PCI to abstinence from
further PCI evenwhere signiﬁcant or high-grade stenosiswas left untreat-
ed. This meant that physiologically signiﬁcant lesions would have been
treated in the same manner as intermediate and mild lesions (N50% ste-
nosis). By deferring high grade stenosis, PRAMI deviated signiﬁcantly
from routine practice where high grade stenoses are known to bender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Table 1
Summarising results from studies using FFR in ACS.
Study/Ref. N Exclusions Study outline Signiﬁcant results
De Bruyne et al. [24]
Circulation 2001
57 Myocardial akinesia, LVSD in
non-culprit territories, diameter
of target vessel b 2.5 mm
FFRa vs SPECT N 6 days post ACS Sensitivity/speciﬁcity: 82%/87%
p b 0.001)
Samady et al. [25]
J Am Coll Cardiol 2006
48 CTO, ongoing ischaemia, haemodynamic
instability, prior MI in index territory,
LMS disease, three vessel disease
FFRa vs SPECT and contrast




Ntalianis et al. [27]
JACC Cardiovasc Interv. 2010
101 Haemodynamic instability FFR measured acutely and 35 +/− 4 days
in non-culprit arteries post ACS
Acute and follow-up FFR:
both 0.77 +/− 0.13
(p = NS)
Sels et al. [28]
JACC Cardiovasc Interv. 2011
328 LMS disease, previous CABG,
STEMI b 5 days prior
Outcomes of using FFR to guide
revascularisation in FAME population
with ACS vs stable angina (SA)
Absolute risk reduction of
ACS vs SA :5.1% vs 3.7%
(p = 0.92)
Lopez-Palop et al. [29]
Rev Esp Cardiol 2012
107 ISR, patients pre-scheduled
for angiography
Outcomes of using FFRa to guide
revascularisation in non-culprit arteries in ACS
MACE of non-treated vs treated group:
7.4% vs 7.7%
(p = 0.52)
MACE — major adverse cardiovascular events (cardiovascular related death, non-fatal MI, urgent revascularisation), CTO — chronic total occlusion, LMS — left main stem,
ISR — in-stent re-stenosis, LVSD — left ventricular systolic dysfunction, CABG — coronary artery bypass graft.
a FFR cut off value used b0.75.
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greater than 50% stenosismeans that a signiﬁcant number of patientswill
receive stents which may be considered physiologically inappropriate.
This strategy of deferral of all lesions greater than 50% stenosis with
physiologically negative lesions to conservative management in the con-
trol arm may also explain why a staged approach to complete
revascularisation of signiﬁcant stenoses confers a prognostic advantage
to immediate PCI of non-culprit vessels [17,18]. It is now recognised
from the French Registry, earlier studies and the RIPCORD study that an-
giography guided revascularisation can bemisleadingwhen compared to
a physiological guided strategy [19,20].
2. Myocardial infarction and micro-vascular disease
There are various theories describing the pathophysiologicalmecha-
nisms underlying micro-vascular dysfunction in the peri-infarct period.
It is hypothesised that endothelial cell integrity is jeopardised in ischae-
mic reperfusion injury, with a subsequent reduction in endothelial de-
rived vasodilators such as nitric oxide and an increase in potent
vasoconstrictors such as endothelin and oxygen free radicals. This cul-
minates in an overall reduction in myocardial ﬂow. Endovascular injury
results in a pro-coagulant and pro-inﬂammatory state caused by a cas-
cade of activated platelets, neutrophils and adhesion molecules known
to mediate myocardial damage [21] (See Fig. 1).
When accompanied by interstitial oedema and cell contraction, this
can result in micro-capillary occlusion. Oxidative stress by the genera-
tion of oxygen free-radicals can directly cause further myocardial injury
to an ischaemic focus. The release of increased intracellular calcium can
alter sarcolemmal calcium regulation which can promote myoﬁbrillar
damage in addition to generating a pro-arrhythmic state [22].
Micro-vascular dysfunction in AMI patients is accepted as occurring
in territories supplied by culprit arteries and forms the mechanism be-
hind the ‘no re-ﬂow’ phenomenon post intervention. Although regional
micro-vascular dysfunction in territories remote from an acutely in-
farcted area has been described [23], small studies have attempted to
address whether this would impact on FFR measurements of non-cul-
prit lesions [12]. This can also aid in the identiﬁcation of culprit lesions
in multi-vessel disease.
3. FFR assessment in AMI
FFR is described as the ratio of maximal hyperaemic myocardial
blood ﬂow in the presence of a coronary stenosis to the normal
hyperaemic blood ﬂow in the same vessel if it were normal. In other
words, the extent to which maximal myocardial blood ﬂow is impeded
by an epicardial stenosis. In order to achieve maximal myocardial ﬂowand tominimise intracoronary resistancewhich is essential in the deter-
mination of the FFR, both the epicardial and microvasculature are
vasodilated. The commonest agent used to ensure vasodilatation is
adenosine [12]. Based on large clinical outcome trials ESC/AHA/ACC
guidelines recommend a cut-off value of less than or equal to 0.80 as a
guide to perform revascularisation [8].
It has been hypothesised that microvascular congestionmay attenu-
ate hyperaemic blood ﬂow, following AMI, leading to a reduced trans-
stenotic pressure gradient. The resulting effect could theoretically lead
to an underestimation of lesion severity producing an artiﬁcially high
FFR reading. Tamita et al. reported that post-interventional FFR was
higher in AMI patients than in the stable angina patients following PCI
with no signiﬁcant differences in IVUS parameters (mean luminal
areas) [9]. Tani et al. described an exploratory ﬁnding in patients post
AMI who had related wall ischaemia on myocardial perfusion single-
photon emission computed tomography (SPECT), but had non-
physiologically signiﬁcant FFR measurements of 0.87 and 0.89 in the
left anterior descending and right coronary arteries respectively. The
mismatch between the diagnostic modalities led the authors to suggest
applying cautionwhen interpreting FFR in culprit lesions postMI [10]. It
is important to note, however, that both of these small studies mea-
sured FFR in the peri-infarct period in culprit arteries only and no as-
sessments were performed in non-culprit bystander lesions.
De Bruyne et al. examined 57 patients at least six days post AMI, the
sensitivity and speciﬁcity of FFRwith a cut-off level of less than 0.75 to de-
tect a perfusion defect on SPECT was 82% and 87%, respectively. When
only true positive and negative SPECT imagingwas considered, the corre-
sponding valueswere 87% and 100% (p b 0.001) [24]. Accordingly, the au-
thors concluded that whenmeasured greater than six days post AMI, FFR
accurately reﬂects the haemodynamic lesion severity and its impact on
myocardial perfusion despite the damaged infarct zone micro-
vasculature.
Samady et al. went on to study 48 patients earlier post AMI
(3.7+/− 1.3 days) than De Bruyne et al. and compared the relationship
of FFRwith SPECT andmyocardial contrast echo. To identify true revers-
ibility, follow-up SPECTwas performed 11weeks after PCI. The sensitiv-
ity, speciﬁcity, and concordance of FFR ≤ 0.75 for detecting true
reversibility on SPECT were 88%, 93%, and 91% (chi-square p b 0.001)
and for detecting reversibility on myocardial contrast echo were 90%,
100%, and 93% (chi-square p b 0.001), respectively. The optimal FFR
value for discriminating inducible ischaemia on non-invasive imaging
was demonstrated as 0.78, similar to ﬁndings from De Bruyne et al.
Thus FFR of the infarct related artery accurately identiﬁed reversibility
on non-invasive imaging, supporting its use early post AMI.
Whilst these studies evolved the physiological ﬁeld towards a grow-
ing population of unstable patients, many of these studies were
Fig. 1. Pathophysiology of microvascular dysfunction post AMI.
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performed 3 days after the acute event. Thus it may be difﬁcult to trans-
late some of the ﬁndings directly to contemporary clinical practice. Ad-
ditionally, in accordance with study design at the time, patients with
occluded infarct-related arteries, haemodynamic instability, prior MI
in the index vessel territory, complex three vessel disease, left main ste-
nosis or ongoing ischaemia were excluded from the study, whereas
nowadays such patients reﬂect a substantial proportion of the patient
population encountered in real world practice. The authors also stated
that the reduction in post MI vasodilator reserve may result in FFR and
non-invasive imaging underestimating the haemodynamic signiﬁcance
of residual lesions in culprit arteries [25].
Ntalianis et al. sought to assess reliability of FFR of non-culprit coro-
nary stenoses during PCI in AMI. 101 patients undergoing PCI for AMI
were prospectively recruited, approximately three quarters of which
were ST elevation MI and one quarter non-ST-elevation MI. FFR mea-
surements in 112 non-culprit stenoses, in which PCI was contemplated
on thebasis of the angiogram (greater than 50% stenosis),were obtained
immediately post PCI of the culprit vessel and repeated 35 +/− 4 days
later. No difference was found between the FFR value of the non-
culprit stenoses between the acute and follow-up phase of the study
(0.77 +/− 0.13 vs. 0.77 +/− 0.13, respectively, P = NS). Only 2
patients had FFR values higher than 0.80 acutely and lower than
0.75 at follow-up but TIMI ﬂow, corrected TIMI frame count, percentage
diameter stenosis, minimum luminal diameter and index of microcircu-
latory resistance (IMR) did not change between the acute and followup
phases. Although IMR did not change, the authors caution that this may
have been due to the relatively short duration between the two mea-
surements [26]. Additionally, most cases included in the study had infe-
rior and lateral wall ST changes on ECG or non-ST-elevation MI.
Haemodynamically unstable patients were also excluded on account
of extensive necrosis and cardiogenic shock precluding hyperaemic as-
sessment of non-culprit stenoses, in linewith acceptedmedical practice.
The study conﬁrmed that non-culprit stenoses with an FFR less than
0.80 underwent PCI at follow-up angiography, and not in the acute set-
ting in line with current guidelines at the time of publication. However,it was not sufﬁciently powered to assess differences in clinical outcome,
but focused on FFR utility as a diagnostic tool in the setting of AMI [27].
Outcome data from a subset analysis from the FAME studymay help
to further support the application of FFR in AMI when the culprit artery
is unknown. Of the original 1005 patients included in FAME, 328 had
unstable angina or non-ST-elevation MI and were included if troponin
titres were positive with creatinine kinase levels less than 1000 units
per litre. Although the analysis was not powered to detect differences
in subgroups, or to detect superiority of one treatment modality over
another, using FFR to guide PCI resulted in similar risk reductions of
major adverse cardiovascular events in patients with unstable angina
and non-ST-elevationMI as those foundwith stable angina. The number
of stents used in this populationwas reducedwithout a concomitant in-
crease in hospital stay or procedure time. Similar to someprevious stud-
ies, extensive ST-elevation MI was excluded on account of presumed
micro-vascular obstruction within an infarcted area causing persistent
myocardial stunning [28].
An observational 2 centre descriptive cohort studywas conducted in
Spain to further observe the use of FFR in safely deciding on manage-
ment in angiographically moderate non-culprit lesions in 107 patients
undergoing PCI for an acute coronary syndrome. Based on FFRmeasure-
ments, 81 patients (75.7%) were not revascularised and all lesions stud-
ied in the remaining 26 patients (24.3%) were revascularised. There
were no signiﬁcant differences in clinical proﬁle or baseline angiograph-
ic characteristics of the two groups studied. At 1 year follow-up, no sig-
niﬁcant differences were observed between the treated group and not-
treated group in terms of cardiac death (p=0.971), revascularisation of
the lesion studied (p=0.8), non-fatalMI orﬁxed combined episode of a
major adverse cardiovascular event (p=0.97). Additionally, therewere
no signiﬁcant differences in need for urgent coronary angiography,
revascularisation or re-hospitalisation due to cardiac causes between
the two groups [29]. These results support the data obtained from the
FAME subgroup analysis, in that the safety and reliability of FFR to assess
the functional signiﬁcance of angiographically inconclusive lesions can
be performed at the same time as culprit lesion revascularisation in
AMI. Aswith FAME and data from Fischer et al. [13], FFR-guided deferral
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ed data from the 5 year follow-up of the DEFER study [30]. As the study
was observational, comparisons could not be made with alternative
non-invasive functional tests, which would have provided an interest-
ing comparison with prior studies [24].
Recent data from a single centre experience of FFR measurement in
non-ST-elevation MI demonstrated a reduction in diagnostic variability
between cardiologists, with the FFR result triggering a change in the ini-
tial treatment decision in 46% of the 100 patients prospectively recruit-
ed [31]. The data collected included measurements of FFR in culprit
lesions in 42% of cases. FFRmay therefore be useful in guiding decisions
regarding revascularisation in AMI by reducing the disparity that exists
between clinicians in the optimal treatment strategy for intermediate
lesions.
4. Practical implications of FFR in AMI
The major advantages associated with FFR measurements include
reproducibility, high degree of spatial resolution [13], high speciﬁcity
when compared with non-invasive modalities such as myocardial
SPECT [10]. FFR provides a practical assessment of physiological signiﬁ-
cance which can be used to provide immediate answers in the cardiac
catheterisation laboratory. However, FFR requiresmaximalmicrovascu-
lar dilatation in order to provide an accurate functional assessment of
coronary lesions [9,19].
As previously mentioned, micro-vascular dysfunction of both the
culprit and non-culprit areas during the acute phase of ST-elevation
MI has been shown in early human studies [26]. Possible pathophysio-
logical mechanisms include local neurohormonal mediated vasocon-
striction, elevated left ventricular end diastolic pressures and
extensive adjacent territory ischaemia [32,33]. Despite this, small stud-
ies have demonstrated that FFR values obtained in non-culprit lesions
during AMI may be reliable and reproducible [11,27–29]. Additionally,
FFR has been validated and incorporated into current guidelines as a
surrogate for ischaemic testing in the cardiac catheterisation laboratory
[13]. Despite this, the necessity to induce hyperaemic conditions using
agents such as adenosine appears to constitute a major deterrent to
the widespread adoption of FFR in clinical practice, particularly in the
United States [34].
Adenosine, although commonly administered for arrhythmias, FFR
assessment and non-invasive imagingmodalities, has contraindications
limiting universal use [35,36]. It is not uncommon for patients with AMI
to present with concurrent atrio-ventricular block, bradycardia, hypo-
tension, severe airway diseases or cardiogenic shock precluding the
use of adenosine to induce hyperaemia in this group [10]. These factors
mean that a proportion of patients presenting with AMI would be inel-
igible for FFR assessment, and other functional or anatomical assess-
ments would be required. Cases of MI and death have been reported
following administration of adenosine or adenosine receptor agonists
[37,38], prompting the United States Food and Drug Administration to
issue a safety announcement in November 2013 advising its avoidance
in patients with cardiovascular instability.
Whilst adenosine is the most frequently used agent, there are alter-
natives with similar efﬁcacy to attain hyperaemia for measurement of
FFR. Nitroprusside administered intracoronary (IC) has yielded similar
vasodilatation to IC adenosine [39]. Rudzinski et al. found that an
intracoronary nitroprusside bolus of 100 μg was at least as effective,
faster acting and better tolerated than conventional intravenous (IV)
adenosine infusion [40]. The use of IC nicorandil as a bolus was found
to be similar in hyperaemic efﬁcacy to that of IV adenosine in 210 pa-
tients studied by Jang et al. [41]. There was also a strong linear correla-
tion between the FFRmeasurements obtained by administration of both
agents (r2= 0.934) with less ﬂuctuation inmean blood pressure, PR in-
terval and chest discomfort following nicorandil administration.
However speed of revascularisation is paramount in AMI and may
preclude the use of FFR. Leesar et al. studied the impact of FFR oncosts, procedural time and clinical outcome of managing AMI. Seventy
patients with recent non-ST-elevationMI or unstable anginawith an in-
termediate single vessel lesion were randomised to either angiography
followed by SPECT, or acute FFR-guided revascularisation. When com-
pared with the SPECT strategy, the FFR-guided approach reduced cost
(US$2113 +/− $120 vs. $1,329 +/− $44, p b 0.05) and hospital dura-
tion, with no signiﬁcant increase in procedure time, radiation exposure
or clinical event rates at 1 year follow-up [42].
5. Alternative assessments of ischaemia
Whilst FFR is the most widely accepted tool for invasive assessment
of coronary lesions, recently novel physiological indices, instant wave-
free ratio (iFR), basal stenosis resistance (BSR) and new imagingmodal-
ities have been introduced which allow physiological investigation
without the need for hyperaemia [43,44]. Whilst the iFR and BSR both
provide rapid on table decision making techniques in a similar way to
FFR, CT-FFR is perhaps less ideal for non-culprit AMI patients as the im-
aging and interpretation takes several hours.
6. Instantaneous wave free ratio (iFR)
Davies et al. identiﬁed a period of the cardiac cycle during which
intracoronary resistance is naturally minimised and stable as observed
duringhyperaemia, thus obviating theneed for pharmacological vasodila-
tation. Data from the Adenosine Vasodilator Independent Stenosis Evalu-
ation Study (ADVISE) and subsequent ADVISE registry, South Korean
Registry, and ADVISE-in Practice studies all showed diagnostic efﬁciency
using iFR to deﬁne a functionally signiﬁcant lesion when compared to
conventional FFR [43,45]. More recently the multicentre, prospective,
core-lab analysed ADVISE II study demonstrated that using a hybrid iFR/
FFR approach delivered an overall classiﬁcation agreement with FFR of
94%, avoiding the need to administer hyperaemic medication in 70% of
patients. The only studywhich has reported different levels of agreement
between iFR and FFR is the VERIFY study [46]. However, when the results
of this studywere independently analysed in core-lab setting, the report-
ed ﬁndings of the VERIFY investigators could not be substantiated, and
high levels of classiﬁcation match between iFR and FFR were identiﬁed.
The reason for this difference has largely been put down to a poor algo-
rithm applied by the VERIFY investigators [47].
The CLARIFY (Classiﬁcation Accuracy of Pressure-Only Ratios
Against Indices using Flow Study) study demonstrated that further re-
ductions in resistance by administration of adenosine when performing
iFR did not improve diagnostic categorisation, when compared to FFR.
The hyperaemic stenosis resistance (HSR) was also used as an arbiter
to determine the most accurate assessment of the haemodynamic sig-
niﬁcance of a lesion when discrepancy existed between iFR and FFR (4
cases, 7.7% of the study population). Although only 51 vessels were
analysed, iFR, iFR with adenosine administration and FFR had an almost
equivalent high level of diagnostic agreement with HSR; with the
receiver-operating characteristic (ROC) area under the curve of 0.93,
0.94 and 0.96, respectively [42].
These studies raise an interesting question as to whether
hyperaemia is even required, when a vasodilator independent method
of coronary analysis can now be performed in the catheter laboratory
with a similar level of diagnostic accuracy to FFR. Using such an ap-
proach would theoretically remove the obstacles encountered in ad-
ministering adenosine to achieve hyperaemia in AMI patients where
microvascular congestion predominates. FFR in small studies has
shown reliability in assessing non-culprit lesions in AMI despite earlier
studies demonstrating microvascular dysfunction in both culprit and
non-culprit territories during acute ST elevationMI. By removing the is-
sues associated with achieving maximal hyperaemia in microcirculato-
ry dysfunction during ACS, iFR may prove a useful non-vasodilator
dependent alternative in some cases to conventional FFR. Encouraging
preliminary data from the FORECAST study supports this premise [48].
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gation of iFR assessment in AMI, andmay circumvent some of the prob-
lems with adenosine administration during FFR measurement.
Whilstmost of the data to date in AMI has been in small patient pop-
ulations, the FLAIR and SWEDEHEART studies will be the ﬁrst studies to
test the application of both FFR and iFR in large contemporary popula-
tions undergoing routine assessment of intermediate non-culprit le-
sions. FLAIR is a global, 2500 patient clinical outcomes trial in which
patients will be randomised to either receiving iFR or FFR guided thera-
py using a single cut-off point (FFR ≤ 0.80, and iFR b 0.90).
7. Conclusions
FFR provides a combination of anatomical and physiological informa-
tion useful in tailoring treatment strategies in coronary artery disease,
with robust clinical data validating its use in stable ischaemic heart dis-
ease. There are small studies supporting the use of FFR in evaluating the
severity of non-culprit lesions during acute coronary syndromes follow-
ing revascularisation of the culprit vessel. It appears to demonstrate diag-
nostic accuracy and reproducibility in AMI, particularly in intermediate
lesions. The presence of microvascular dysfunction as observed in exper-
imental and clinical studies in non-culprit arterial territories appears to
not signiﬁcantly hinder FFR calculation. However, larger studies such as
FLAIR and SWEDEHEART are needed to validate these ﬁndings.
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